An Open, Prospective, Non-interventional, Multicentre, Controlled Study of Safety and Efficacy of the Thrombolysis With the Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke (FORPI Registry)
Latest Information Update: 05 Dec 2024
Price :
$35 *
At a glance
- Drugs Recombinant staphylokinase Supergene (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms FORPI
- Sponsors Supergene
- 02 Dec 2024 New trial record